Anthony Macarthy, MD
Family Medicine · Silver Spring, MDNPI 1629300470
Payments from drug & device makers
Across 225 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$444
- Lilly USA, LLC$351
- Gilead$291
- Novartis$283
- Lundbeck LLC$262
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,05298%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 69 | $1,108 |
| Otsuka America Pharmaceutical, Inc. | 25 | $444 |
| Lilly USA, LLC | 15 | $351 |
| Gilead | 15 | $291 |
| Novartis | 18 | $283 |
| Lundbeck LLC | 15 | $262 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $233 |
| Pfizer | 8 | $217 |
| Astellas Pharma US Inc | 5 | $146 |
| Kowa Pharmaceuticals America, Inc. | 7 | $101 |
| Amgen | 5 | $100 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $99 |
| Biohaven Pharmaceuticals, Inc. | 5 | $92 |
| Exact Sciences | 4 | $76 |
| Smith+Nephew | 2 | $58 |
| Boehringer Ingelheim | 2 | $45 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $39 |
| Phadia US Inc. | 2 | $36 |
| GSK | 2 | $36 |
| Novo Nordisk | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Abbott | 1 | $19 |
| Alkermes, Inc. | 1 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
| Eisai Inc. | 1 | $13 |
How this compares
$4,127 in reported general payments places this provider in the 85th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 142 | $81,578 |
| EntrestoSacubitril/Valsartan | 17 | $18,490 |
| XareltoRivaroxaban | 22 | $11,986 |
| LinzessLinaclotide | 19 | $10,491 |
| SantylCollagenase Clostridium Hist. | 17 | $8,427 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $5,711 |
| Atorvastatin Calcium | 326 | $4,143 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,575 |
| Mirtazapine | 132 | $2,716 |
| Quetiapine Fumarate | 133 | $2,523 |
| Metolazone | 59 | $2,355 |
| Aripiprazole | 36 | $2,274 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 75 | $2,034 |
| Megestrol Acetate | 13 | $2,029 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 59 | $2,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $217 | $83,073161 claims |
| NovartisEntresto | $283 | $18,49017 claims |
| AbbVieLinzess | $1,108 | $10,49119 claims |
| Smith+NephewSantyl | $58 | $8,42717 claims |
| GSKBreo Ellipta | $36 | $5,71115 claims |
| Lilly USA, LLCOlanzapine | $351 | $1,79148 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Silver Spring
- Cynthia KleppingerSilver Spring$51K
- Jean WelshSilver Spring$26K
- Stephen OngOxon Hill$5.9M
- Stephan BartWoodstock$1.7M
- Karen DonaldsonBaltimore$899K
- Rajiv DuaColumbia$765K
- Greg TampusLutherville Timonium$735K
- Louis JacquesBaltimore$522K
- Stephanie MellerOxon Hill$518K
- Sharon ChungGlen Burnie$333K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.